Combined Neprilysin and RAS Inhibition in Cardiovascular Diseases: A Review of Clinical Studies

Journal of Cardiovascular Pharmacology

Volumn 68, Issue 3, 2016, Pages 183-190

  Tummala, Ramyashree ^a   Bhadra, Rajarshi ^a   Gupta, Anjan ^a   Ghosh, Raktim K ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

candoxatril; ecadotril; Heart failure; LCZ696; natriuretic peptide; neprilysin inhibition; PARADIGMHF; PARAMOUNT; sacubitril valsartan

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 CARBOXY 1 BUTYLCARBAMOYL)PROPIONIC ACID; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CANDOXATRIL; ENALAPRIL; GLYCERYL TRINITRATE; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; OMAPATRILAT; PLACEBO; SACUBITRIL; SACUBITRIL PLUS VALSARTAN; SINORPHAN; VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; TETRAZOLE DERIVATIVE;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG USE; HEART FAILURE; HUMAN; HYPERTENSION; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; TREATMENT PLANNING; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROCEDURES;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; NEPRILYSIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 84964374787     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000402     Document Type: Article

References (64)

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics 2015 update: a report from the American Heart Association. Circulation. 2015;131:e29-e322.
2. The global health and economic burden of hospitalizations for heart failure lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123-1133.
3. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10:933-989.
4. McMurray JJ, Adamopoulos S, Anker SD, et al. Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 33:1787-1847.
5. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953-1959.
6. Yu CM, Lin H, Yang H, et al. Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation. 2002;105:1195-1201.
7. Borlaug BA, Kass DA. Ventricular-vascular interaction in heart failure. Heart Fail Clin. 2008;4:23-36.
8. Jackson G, Gibbs CR, Davies MK, et al. Pathophysiology. BMJ. 2000; 320:167-170.
9. Lang CC, Struthers AD. Targeting the renin-angiotensin-aldosterone system in heart failure. A review detailing the different therapeutic methods available and under investigation for targeting the RAAS. Nat Rev Cardiol. 2013;10:125-134.
10. von Lueder TG, Sangaralingham SJ, Wang BH, et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail. 2013;6:594-605.
11. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J. 1997;133:703-712.
12. Yancy CW, Jessup M, Bozkurt B. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American heart association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-e239.
13. Go AS, Mozaffarian D, Roger VL. Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129:399-410.
14. Desai AS, Stevenson LW. Rehospitalization for heart failure, predict or prevent? Circulation. 2012;126:501-506.
15. Braunwald E. Heart failure. JACC Heart Fail. 2013;1:1-20.
16. Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 2002;91:1127-1134.
17. Potter LR, Yoder AR, Flora DR, et al. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009;191:341-366.
18. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007; 50:2357-2368.
19. Dell'Italia LJ. Translational success stories: angiotensin receptor 1 antagonists in heart failure. Circ Res. 2011;109:437-452.
20. He BJ, Anderson ME. Aldosterone and cardiovascular disease: the heart of the matter. Trends Endocrinol Metab. 2013;24:21-30.
21. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006;27:47-72.
22. Soeki T, Kishimoto I, Okumura H, et al. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol. 2005;45:608-616.
23. Sangaralingham SJ, Huntley BK, Martin FL, et al. The aging heart, myocardial fibrosis, and its relationship to circulating Ctype natriuretic Peptide. Hypertension. 2011;57:201-207.
24. von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther. 2014;144:41-49.
25. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
26. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011; 365:32-43.
27. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900-1905.
28. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491.
29. Ahmad T, Felker GM. Subcutaneous B-type natriuretic peptide for treatment of heart failure: a dying therapy reborn? J Am Coll Cardiol. 2012; 60:2313-2315.
30. Cataliotti A, Costello-Boerrigter LC, Chen HH, et al. Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension. Mayo Clin Proc. 2012;87:413-415.
31. Ruschitzka F, Corti R, Quaschning T, et al. Vasopeptidase inhibitors-concepts and evidence. Nephrol Dial Transpl. 2001;16:1532-1535.
32. Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-Centre Dose-Ranging Study Investigators. Lancet. 1998;351:1657-1658.
33. McDowell G, Coutie W, Shaw C, et al. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol. 1997;43:329-332.
34. Martin FL, Stevens TL, Cataliotti A, et al. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int. 2005;67:1723-1730.
35. Von Lueder TG, Sangaralingham SJ, et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail 2013;6:594-605.
36. Burrell LM, Farina NK, Balding LC, et al. Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure. Hypertension. 2000;36:1105-1111.
37. Maki T, Nasa Y, Tanonaka K, et al. Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation. J Pharmacol Exp Ther. 2003;305:97-105.
38. Sampaio WO, Nascimento AA, Santos RA. Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol. 2003;284:H1985-H1994.
39. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000; 356:615-620.
40. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920-926.
41. Weber MA. Vasopeptidase inhibitors. Lancet. 2001;358:1525-1532.
42. Feng L, Karpinski PH, Sutton P, et al. LCZ696: a dual-acting sodium supramolecular complex. Tetrahedron Lett. 2012;53:275-276.
43. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor2neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401-414.
44. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
45. Hegde LG, Yu C, Renner T, et al. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J Cardiovasc Pharmacol. 2011;57:495-504.
46. von Lueder TG, Wang BH, Kompa AR, et al. The angiotensin-receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015;8:71-78.
47. Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a firstin-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63:698-705.
48. Ruilope LM, Dukat A, Bohm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255-1266.
49. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380: 1387-1395.
50. Shah RV, Desai RS, Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalizations in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. J Card Fail. 2010;16:260-267.
51. Jhund PS, Claggett B, Packer M, et al. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail. 2014; 16:671-677.
52. McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15:1062-1073.
53. McMurray JJ, Packer M, Desai AS, et al. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to Determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014;16:817-825.
54. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
55. Claggett B, Packer M, McMurray JJ, et al; PARADIGM-HF Investigators. Estimating the long-term treatment benefits of sacubitril-valsartan. N Engl J Med. 2015;373:2289-2290.
56. Matthew P, Lillyblad MP. Dual angiotensin receptor and neprilysin inhibition with sacubitril/valsartan in chronic systolic heart failure: understanding the new paradigm. Ann Pharmacother. 2015;49: 1237-1251.
57. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30-41.
58. Clark H, Krum H, Hopper I. Worsening renal function during renin-angiotensin aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction. Eur J Heart Fail. 2014;14:41-48.
59. Bodey F, Hopper I, Krum H. Neprilysin inhibitors preserve renal function in heart failure. Int J Cardiol. 2015;179:329-330.
60. ClinicalTrials. gov. A Service of the U. S. National Institutes of Health. Available at: https://clinicaltrials. gov/ct2/results?term=lcz696&Search=Search. Accessed November 1, 2015.
61. Miners JS, Barua N, Kehoe PG, et al. Ab-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol. 2011;70:944-959.
62. Dawson LA, Maitland NJ, Turner AJ, et al. Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression. Br J Cancer. 2004;90:1577-1582.
63. Guo X, Tang P, Liu P, et al. Meta-analysis of the association between two neprilysin gene polymorphisms and Alzheimer's disease. J Neurol Sci. 2014;346:6-10.
64. Smollich M, Gotte M, Yip GW, et al. On the role of endothelinconverting enzyme-1 (ECE-1) and neprilysin in human breast cancer. Breast Cancer Res Treat. 2007;106:361-369.